In the latest close session, Medpace (MEDP) was down 1.49% at $530.19. The stock trailed the S&P 500, which registered a daily loss of 0.79%. At the same time, the Dow lost 0.26%, and the tech-heavy Nasdaq lost 1.55%.
Shares of the provider of outsourced clinical development services have appreciated by 15.17% over the course of the past month, outperforming the Medical sector's gain of 5.5%, and the S&P 500's gain of 4.28%.
The upcoming earnings release of Medpace will be of great interest to investors. The company's earnings report is expected on July 22, 2026. The company's upcoming EPS is projected at $4.08, signifying a 31.61% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $699.51 million, up 15.95% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $17.04 per share and revenue of $2.79 billion, indicating changes of +11.52% and +10.32%, respectively, compared to the previous year.
Investors should also note any recent changes to analyst estimates for Medpace. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Medpace is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Medpace is holding a Forward P/E ratio of 31.59. For comparison, its industry has an average Forward P/E of 15.5, which means Medpace is trading at a premium to the group.
We can additionally observe that MEDP currently boasts a PEG ratio of 2.73. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. MEDP's industry had an average PEG ratio of 1.44 as of yesterday's close.
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 109, positioning it in the top 45% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Medpace Holdings, Inc. (MEDP): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).